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Summary
 
Understanding the regulation of cell surface expression of specific peptide–major histocompat-
ibility complex (MHC) complexes is hindered by the lack of direct quantitative analyses of spe-
cific peptide–MHC complexes. We have developed a direct quantitative biochemical approach
by engineering soluble divalent T cell receptor analogues (TCR–Ig) that have high affinity for
their cognate peptide–MHC ligands. The generality of this approach was demonstrated by spe-
cific staining of peptide-pulsed cells with two different TCR–Ig complexes: one specific for
the murine alloantigen 2C, and one specific for a viral peptide from human T lymphocyte vi-
rus–1 presented by human histocompatibility leukocyte antigens–A2. Further, using 2C TCR–
Ig, a more detailed analysis of the interaction with cognate peptide–MHC complexes revealed
several interesting findings. Soluble divalent 2C TCR–Ig detected significant changes in the
level of specific antigenic–peptide MHC cell surface expression in cells treated with 
 
g
 
-inter-
feron (
 
g
 
-IFN). Interestingly, the effects of 
 
g
 
-IFN on expression of specific peptide–MHC
complexes recognized by 2C TCR–Ig were distinct from its effects on total H-2 L
 
d
 
 expression;
thus, lower doses of 
 
g
 
-IFN were required to increase expression of cell surface class I MHC
complexes than were required for upregulation of expression of specific peptide–MHC com-
plexes. Analysis of the binding of 2C TCR–Ig for specific peptide–MHC ligands unexpectedly
revealed that the affinity of the 2C TCR–Ig for the naturally occurring alloreactive, putatively,
negatively selecting, complex, dEV-8–H-2 K
 
bm3
 
, is very low, weaker than 71 
 
m
 
M. The affinity
of the 2C TCR for the other naturally occurring, negatively selecting, alloreactive complex,
p2Ca–H-2 L
 
d
 
, is 
 
z
 
1000-fold higher. Thus, negatively selecting peptide–MHC complexes do
not necessarily have intrinsically high affinity for cognate TCR. These results, uniquely re-
vealed by this analysis, indicate the importance of using high affinity biologically relevant cog-
nates, such as soluble divalent TCR, in furthering our understanding of immune responses.
 
A
 
ntigenic specificity of cellular immune responses is
controlled by the recognition of a particular peptide–
MHC complex by the clonotypic T cell receptor. Identifi-
cation and quantitation of peptide–MHC complexes on
the surface of APCs, both in vitro and in vivo, have been
difficult. This difficulty is due to a variety issues: the low
number of specific peptide–MHC complexes on individual
APCs; the low intrinsic affinity of soluble probes for spe-
cific peptide–MHC complexes; and the nonquantitative, in-
direct nature of cellular readouts. Although cellular assays
have greatly facilitated analysis of peptide–MHC complex
expression, these assays, which involve readouts such as cytol-
ysis, lymphokine secretion, or cell proliferation, are not ex-
clusively dependent upon specific antigenic peptide–MHC
complexes, but are also highly influenced by differences in
costimulation (1, 2). The complexities associated with cel-
lular-based assays have led investigators to develop biochem-
ical analogues to directly analyze peptide–MHC expression.
Several approaches have been taken to study expression
of specific peptide–MHC complexes using soluble ligands.
A traditional soluble ligand-based approach is to generate
mAbs specific for particular peptide–MHC complexes. Al-
though theoretically this approach is appealing, practically,
only a few such antibodies with high enough specificity for
a particular peptide–MHC class I or class II complexes have
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been generated (3–7). Recently a new approach using a re-
combinant antibody phage display library was used to gen-
erate a relatively low affinity Fab antibody that was specific
for a particular peptide–MHC complex (8). A second ap-
proach  has entailed using soluble TCR analogues. A variety
of different approaches have been used to develop soluble
analogues of TCR (for review see reference 9). Similar to the
natural peptide–MHC specificity of T cells, soluble ver-
sions of TCR have the requisite peptide specificity useful
in probing specific antigenic peptide–MHC complexes. Al-
though these reagents have been invaluable in defining the
basic biochemistry involved in TCR interaction with pep-
tide–MHC complexes (10–12), the intrinsic low affinity of
these reagents limits their use in the direct identification
and quantitation of peptide–MHC complexes.
The relationship between the affinity of a TCR for a
specific peptide–MHC complex and the physiologic re-
sponses of T cells is poorly understood. In the 2C system,
this is particularly relevant since, using CTL-based assays,
several naturally occurring and synthetically derived cog-
nate peptide–MHC ligands have been defined (13–17).
However, the affinity of the 2C TCR for only one of the
known naturally occurring cognate peptide–MHC ligands
has been measured (12, 14). Specifically, the 2C TCR is al-
loreactive on two different MHC complexes (18–20), H-2
L
 
d
 
 and H-2 K
 
bm3
 
. Both H-2 L
 
d
 
 and H-2 K
 
bm3
 
 mediate neg-
ative selection of the 2C TCR in 2C transgenic mice (20).
With regard to the alloresponse on H-2 K
 
bm3
 
, a single
HPLC peak containing one peptide, dEV-8, that can medi-
ate lysis of H-2 K
 
bm3
 
 target cells by 2C CTL has been de-
fined (21, 22). This complex is the presumptive peptide–
MHC complex involved in negative selection of the 2C TCR
in H-2 K
 
bm3
 
 mice and might be expected to be of high af-
finity. Soluble, high affinity probes for specific peptide–MHC
complexes can be used to gain insights into the relationship
between the affinity of a TCR for a specific peptide–MHC
complex and the biological impact that same peptide–
MHC complex has on T cells.
Soluble, high affinity probes for specific peptide–MHC
complexes were developed, in part, to study the role of lym-
phokines such as 
 
g
 
-IFN on antigen expression. 
 
g
 
-IFN is
known to have multiple sites of action that regulate expres-
sion of peptide–class I MHC complex expression (23–27).
 
g
 
-IFN is known to impact on antigen presentation by in-
creasing transcription of both class I heavy chain and TAP
(transporter associated with antigen processing) genes (23).
 
g
 
-IFN also regulates the proteasome by controlling expres-
sion of low molecular mass polypeptide (LMP)2, LMP7,
and the proteasome regulator PA28
 
a
 
 (25). Recent studies
have shown that induction of the proteasome regulator
PA28
 
a
 
 influences both the amount and sequence of pep-
tides generated by the proteasome (24, 28). It is not clear if
the effects of 
 
g
 
-IFN on different parts of the antigen pro-
cessing pathway are coordinated. Is the effect of 
 
g
 
-IFN on
increased expression of class I heavy chain seen at the same
dose of 
 
g
 
-IFN as are effects on increases in specific anti-
gen–MHC complex expression? This is an important issue
as discordant effects of 
 
g
 
-IFN may have implications for
understanding the influence of 
 
g
 
-IFN immune responses.
The development of a high affinity reagent could be used to
analyze the impact 
 
g
 
-IFN on endogenous antigen–MHC
complex expression.
We have developed a general system for expression of
soluble high affinity TCR analogues. Using Ig as a molecu-
lar scaffold, soluble divalent TCR analogues were generated
and used to analyze the interaction with cognate peptide–
MHC complexes. The system utilized used the 2C TCR
which is derived from alloreactive 2C CTL (13, 29) and
the A6 TCR, which is specific for a viral peptide derived
from the HTLV-1 tax protein (30, 31). The divalent nature
of the TCR analogue significantly increased the affinity for
peptide–MHC complexes while retaining the peptide spec-
ificity of the native TCR. (Since TCR–Ig was designed as a
probe for peptide–MHC complexes its effective affinity/
avidity for such complexes is more relevant than the intrin-
sic affinity of each TCR combining site for specific peptide–
MHC complexes. For this reason, we refer to the effective
affinity/avidity of 2C TCR–Ig for peptide–MHC com-
plexes simply as affinity throughout the text.) Due to this
increased affinity, TCR–Ig chimeras were useful in direct
flow cytometry experiments to detect specific peptide–
MHC complexes. Using the 2C TCR–Ig, we have analyzed
the correlation between affinity of the TCR for specific
peptide–MHC complexes and lysis of target cells expressing
the same peptide–MHC complexes. Furthermore, using
2C TCR–Ig, we were also able to directly analyze the
modulatory effects of 
 
g
 
-IFN on expression of endogenous
2C TCR reactive peptide–MHC complexes.
 
Materials and Methods
 
Cells and Culture Conditions
 
RMA-S, RMA-S L
 
d
 
, T2, T2 K
 
b
 
, T2 K
 
bm3
 
, T2 K
 
bm11
 
, and
RENCA cells were maintained by 1:10 passage three times
weekly in RPMI-1640 supplemented with 2 mM glutamine,
nonessential amino acids, 50 
 
m
 
g/ml of gentamicin, 5 
 
3
 
 10
 
2
 
5
 
 M
2-mercaptoethanol, and 10% fetal calf serum.
 
Expression of Soluble Divalent TCR Analogues
 
The details of construction, expression, purification, and char-
acterization of soluble divalent 2C TCR–Ig and A6 TCR–Ig
were carried out as described elsewhere (O’Herrin, S.M., M.S.
Lebowitz, and J.P. Schneck, manuscript in preparation). In brief,
to generate the soluble divalent TCR, cDNAs encoding the
TCR 
 
a
 
 and 
 
b
 
 chains were genetically linked via glycine/serine
spacer to cDNAs encoding IgG1 heavy chains and kappa light
chains, respectively (see Fig. 1 for protein schematic). Soluble
monovalent 2C TCR was made and purified as previously de-
scribed (12).
 
Biochemical Analysis of Soluble TCR–Ig
 
The chimeric TCR–IgG proteins were detected by ELISA as-
says specific for the chimeric protein. The primary antibody used
was specific for murine IgG1 Fc and a biotinylated second anti-
body was either mAb 1B2 (29, 32), a murine mAb specific for a
clonotypic epitope expressed on 2C TCR, or the anti–human
V
 
b
 
13.1, H131.21Y (see Fig. 1 for the proposed mAb binding
sites). Wells were incubated with the primary antibody, 10 
 
m
 
g/ 
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ml, for 1 h at room temperature, and then blocked with a 2%
BSA solution before use. After three washes with PBS containing
0.05% Tween 20 and 1% FCS, culture supernatants (100 
 
m
 
l) from
baculovirus infected cells containing the soluble divalent TCR–Ig
were incubated for 1 h at room temperature. Plates were then
washed extensively and then incubated with the biotinylated sec-
ond antibody. When using biotinylated second antibody, wells
were incubated with 100 
 
m
 
l 10% mouse serum for an additional
hour to reduce background reactivity. After 1 h incubation with
the biotinylated antibody, the plates were washed and incubated
with horseradish peroxidase–conjugated strepavidin (100 
 
m
 
l of a
1:10,000 dilution) for 1 h, washed, and developed with 3,3
 
9
 
,5,5
 
9
 
-
tetramethylbenzidine dihydrochloride (TMB) substrate for 3–5
min. The reaction was stopped by the addition of 1 M H
 
2
 
SO
 
4
 
and optical density was measured at 450 nm.
 
Peptide Loading of Cells
 
RMA-S and T2 cell lines are defective in antigen processing
and express functionally “empty” class I MHC on their cell surface
(33, 34). These empty MHC molecules may be loaded with pep-
tides as described (35, 36). In brief, cells (RMA-S, RMA-S L
 
d
 
,
T2, T2 L
 
d
 
, T2 K
 
b
 
, T2 K
 
bm3
 
 or T2 K
 
bm11
 
) were cultured at 27
 
8
 
C
overnight. Subsequently, cells were incubated in the presence or
absence of various antigenic peptides (100 
 
m
 
M final concentra-
tion) for an additional 1.5 h at 27
 
8
 
C and then for 1 h at 37
 
8
 
C.
RENCA cells were loaded with peptides by incubation with
peptides (100 
 
m
 
M final concentration) for 
 
.
 
2 h at 37
 
8
 
C. Cells were
then harvested and processed for FACS
 
Ò
 
 (Becton Dickinson, San
Jose, CA) analysis as described.
All peptides were made by the Johns Hopkins University (Bal-
timore, MD) biopolymer laboratory peptide synthesis facility by
F-MOC chemical synthesis and then purified by preparative
HPLC. Sequences were confirmed by amino acid analysis and pro-
tein sequencing. Sequences of the peptides and the known affini-
ties of monovalent 2C TCR for specific peptide–H-2 L
 
d
 
 com-
plexes are shown in Table 1. The HLA-A2–restricted peptides used
were: the HTLV-1–derived peptide tax (37), LLFGYPVYV, and
the influenza-derived peptide, M1, GILGFVFTL.
 
Direct Flow Microfluorimetry
 
For analysis of 2C TCR–Ig specificity, 
 
z
 
3 
 
3
 
 10
 
5
 
 peptide-
loaded or control cells were incubated for 60 min at 4
 
8
 
C with ei-
ther 
 
z
 
50 
 
m
 
g/ml mAb 30.5.7 culture supernatants in a 30–50 
 
m
 
l
volume, 50 
 
m
 
l of 2C TCR–Ig culture supernatants (10 
 
m
 
g/ml fi-
nal concentration), or 25–50 
 
m
 
g/ml purified 2C TCR–Ig in a 30
 
m
 
l volume. For analysis of A6 TCR–Ig specificity, 
 
z
 
3 
 
3
 
 10
 
5
 
peptide-loaded or control cells were incubated for 60 min on ice
with either 
 
z
 
50 
 
m
 
g/ml of the HLA-A2–reactive mAb BB7.2, or
50 
 
m
 
l of A6 TCR–Ig culture supernatants (1–10 
 
m
 
g/ml final con-
centration). Cells were then washed once in 1
 
3
 
 PBS, 1% FBS,
and 0.02% Na-azide (wash buffer), and then incubated for an ad-
ditional 60 min at 4
 
8
 
C in 20 
 
m
 
l of a 1/40 dilution goat anti–
mouse IgG–red algae phycoerythrin (Southern Biotechnology
Assoc., Inc., Birmingham, AL). Cells were subsequently washed
once with wash buffer, resuspended in 250 
 
m
 
l wash buffer and
analyzed on a FACScan
 
Ò
 
 flow cytometer.
 
Measurement of the Affinity of Soluble 2C TCR
for H-2 L
 
d
 
 Molecules
 
Affinities of soluble 2C TCR analogues for peptide loaded
cells were determined in a competition assay with FITC-30.5.7
Fab similar to one previously described (38). 30.5.7 is a mAb that
recognizes an epitope near the peptide-exposed face of H-2L
 
d
 
;
thus 30.5.7 and 2C TCR compete for binding to the peptide ex-
posed face of H-2L
 
d
 
. K
 
d
 
 of 30.5.7 Fab for peptide-loaded RMA-S
L
 
d
 
 cells were determined as follows. Cells (0.3 
 
3
 
 10
 
6
 
/10 
 
m
 
l) were
loaded with peptide as described above. Subsequently, peptide-
loaded or control cells were incubated with varying concentra-
tions of FITC-30.5.7 Fab for 1 h at 4
 
8
 
C, and then diluted 1:6
with wash buffer immediately before analysis by flow cytometry.
K
 
d were estimated from a plot of 1/(mean channel fluorescence)
versus 1/[FITC-30.5.7 Fab].
Affinities of 2C TCR analogues were determined by competi-
tion with constant concentrations of FITC-30.5.7 Fab. Cells
were loaded with peptide, and subsequently incubated with a
constant concentration of FITC-30.5.7 Fab and varying concen-
trations of 2C TCR analogues for 1 h at 48C. Cells were diluted
1:6 with wash buffer immediately before analysis by flow cytom-
etry. Maximal inhibition of FITC-30.5.7 Fab binding was deter-
mined by incubation in the presence of 30.5.7 mAb (75 mg). Kapp
was determined from a plot of 1/(percent maximal inhibition)
versus [2C TCR analogue]. Kapp was corrected for the affinity of
FITC-30.5.7 Fab for peptide loaded cells according to the equa-
tion Kd,TCR 5 Kapp/(1 1 ([FITC 30.5.7 Fab]/Kd,30.5.7)) (38).
CTL Experiments
Generation of CTLs. Splenocytes from 2C TCR transgenic
mice (18) were resuspended at 1.25 3 106/ml and stimulated
with 1.75 3 106 BALB/c splenocytes that had been exposed to
3,000 cGy radiation. On day 7, the 2C T cell–enriched cultures
were restimulated at 5 3 105/ml with 2.5 3 106/ml BALB/c
splenocytes. Experiments were performed on this and subsequent
stimulation on day 4. All subsequent stimulation was performed
with 3.75 3 105/ml 2C splenocytes and 2.5 3 106/ml BALB/c
cells in the presence of IL-2 (5 U/ml).
CTL assays. Assays were performed in triplicate according to
established CTL protocols. In brief, target cells (2–4 3 106) were
incubated with 100 mCi 51Cr at 378C for 1 h. After three washes,
cells were added to V-bottomed 96-well plates (3 3 103/100 ml)
and incubated (258C for 1.5 h) with peptides at the indicated
concentrations. 2C T cells (3 3 104/100 ml) were added to tar-
gets and plates were incubated at 378C for 4.5 h. Maximum re-
lease was achieved by incubating targets with 5% Triton-X 100.
Percent specific lysis was calculated from raw data using ([experi-
mental release 2 spontaneous release]/[maximum release 2
spontaneous release]) 3 100.
Results
Model Systems Used for Generating Soluble Divalent
TCR. The well-characterized 2C TCR was chosen as a
model system for constructing soluble divalent TCR. 2C is
an alloreactive, peptide-specific CTL clone derived from
H-2b–expressing mice (29). This clone is specific for a nat-
urally processed endogenous peptide, p2Ca, derived from
a-ketoglutarate dehydrogenase bound by the murine class I
molecule H-2 Ld (13). The importance of this response can
be seen by the fact that p2Ca-like peptides are known to
dominate certain murine alloreactive responses in strains
expressing Vb81 TCR (39). Both higher affinity, peptide
QL9, and lower affinity, peptide SL9, variants of p2Ca re-
active with 2C cells also have been generated (Table 1; ref-1336 Analysis of Peptide–MHC Complexes by TCR–Ig
erences 14, 15). In addition, to peptide/H-2 Ld ligands for
2C TCR, two peptides that sensitize either H-2 Kb or H-2
Kbm3 targets for lysis by 2C CTLs have also been defined
(17, 22). dEV-8 is a peptide isolated from H-2 Kbm8 target
cells that induces effective lysis of H-2 Kbm3 targets by 2C
CTL (22). The deduced sequence of dEV-8 matches that
of an endogenous peptide derived from the mitochondrial
MLRQ protein. Another peptide, SIYRYYGL (SIY), was
isolated from a random peptide library on the basis of its
ability to mediate strong lysis of H-2 Kb target cells by 2C-
CTL (17). This series of peptides facilitates the study of sol-
uble divalent 2C TCR–Ig chimeras on a variety of differ-
ent peptide–MHC ligands representing a wide range of af-
finities for the 2C TCR.
The TCR derived from the HTLV-specific CTL clone
A6 was chosen as another model system. HTLV-1–associ-
ated myelopathy/tropical spastic paraparesis (HAM/TSP) is
a paralytic disease associated with HTLV-1 infection (40,
41). In patients with HAM/TSP, an extremely high fre-
quency of HTLV-1–specific T cells has been seen, up to
40–280-fold higher than in asymptomatic patients (37, 41).
A dominant peptide antigen derived from the HTLV-1 tax
protein, recognized by virus specific CTLs, has been de-
fined in a subset of the patients, those who express HLA-
A2 (31, 42). Although CTL responses to the dominant tax-
derived peptide and variants thereof have been identified,
no affinity measurements for the interaction of the A6
TCR with cognate peptide–HLA-A2 complexes have
been reported (30, 43). Thus, this system also represents an
interesting one for analysis using soluble high affinity diva-
lent TCR–Ig complexes.
To generate soluble divalent TCRs, cDNAs encoding
the TCR a and b chains were genetically linked to cDNAs
encoding IgG1 heavy chains and kappa light chains, respec-
tively (see Fig. 1 A for protein schematic and O’Herrin,
S.M., M.S. Lebowitz, and J.P. Schneck, manuscript in
preparation, for details of construction). For expression,
Trichoplusia ni. cells were infected with a baculovirus ex-
pression vector encoding the soluble divalent 2C TCR–Ig
constructs. Chimeric 2C TCR–Ig and A6 TCR–Ig could
be easily purified from culture supernatants and retained
epitopes associated with Ig portions of the molecule
(O’Herrin, S.M., M.S. Lebowitz, and J.P. Schneck, manu-
script in preparation).
The chimeric TCR–Ig proteins are conformationally in-
tact (Fig. 1 B and C). The soluble divalent 2C TCR–Ig was
reactive with 1B2, the anti-clonotypic mAb determinant spe-
cific for the 2C TCR (Fig. 1 B) as well as with H57, a mAb
specific  for a conformational epitope expressed on murine
TcR Cb chains (data not shown). Soluble divalent A6 TCR–
Ig was reactive only with the Vb13.1-specific mAb, H131.21Y
(Fig. 1 C) and, as expected, not reactive with mAb 1B2
(Fig. 1 B). Control baculovirus infected supernatants were
not reactive with either of the mAb (Fig. 1, B and C).
Binding Specificity of Soluble Divalent TCR Chimeras to
Peptide-loaded MHC Molecules. Based on the divalent na-
ture of the soluble TCR–Ig complexes, we postulated that
the molecules would have a high affinity for cognate pep-
tide–MHC complexes. The high affinity of the soluble di-
valent TCR analogues could make them useful in analysis
of peptide–MHC complexes by routine direct flow cytom-
etry-based assays. Because of their intrinsic low affinity, sol-
uble monovalent TCR analogues have routinely not been
useful in direct flow cytometry–based assays. To study pep-
tide specificity of TCR–Ig, we compared reactivity of 2C
TCR–Ig with that of H-2 Ld reactive mAb 30.5.7, and A6
TCR–Ig with that of BB7.2, in direct flow cytometry–
based assays.
Table 1. Peptides Used in this Study: Their Reported Effectiveness in 2C CTL Assays and Affinities of 2C TCR for Peptide–MHC 
Complexes
Peptide name Peptide sequence MHC restriction 2C-mediated lysis Kd
mM
p2Ca LSPFPFDL H-2 Ld 111 0.5-0.1
QL9 QLSPFPFDL H-2 Ld 1111 0.066
SL9 LSPFPFDLL H-2 Ld 1/2 71
tum2 TQNHRALDL H-2 Ld na na
pMCMV YPHFMPTNL H-2 Ld 2 nd
gp 70 SPSYVYHQF H-2 Ld na na
dEV-8 EQYKFYSV H-2 Kb 2 Unknown
dEV-8 – H-2 Kbm3 111 Unknown
SIY SIYRYYGL H-2 Kb 111 Unknown
SIY – H-2 Kbm3 Unknown Unknown
pVSV NP(52–59) RGYVYQGL H-2 Kb 2 nd
na, not available; nd, none detected (the affinity was below the sensitivity of the assay used).
Peptides listed are a collection of H-2 Ld– and H-2 Kb–binding peptides used in analysis of the reactivity of the soluble divalent 2C TCR–Ig. Lysis 
and affinity data are summarized from their primary references (12, 14, 15, 17, 22, 57–59).1337 O’Herrin et al.
The temperature-dependent reactivity of RMA-S Ld
with 2C TCR–Ig was significantly different than the reac-
tivity of RMA-S Ld with mAb 30.5.7. As expected (44, 45),
RMA-S Ld cells, cells that express empty MHC molecules,
expressed more serologically reactive H-2 Ld molecules
recognized by mAb 30.5.7 on cells cultured at 278C than
when cells were cultured at 378C (Fig. 2 A); mean channel
fluorescence (MCF)1 increased approximately fivefold.
Thus, the epitope on H-2 Ld molecules recognized by mAb
30.5.7 can be stabilized by incubating cells at low tempera-
tures. In contrast, RMA-S Ld cells expressed very low
amounts of H-2 Ld molecules recognized by 2C TCR–Ig
on cells cultured at either 27 or at 378C (Fig. 2, E). This
finding is consistent with the expected peptide-dependent
reactivity of 2C TCR–Ig which should not recognize
MHCs that have not been pulsed with peptides even when
conformationally stabilized by decreased temperature.
2C TCR–Ig reactivity showed exquisite peptide specificity.
Peptides (see Table 1 for sequences) were loaded into
empty H-2 Ld molecules on RMA-S Ld cells. As expected,
all H-2 Ld–binding peptides stabilized expression of the
epitope recognized by mAb 30.5.7 (Fig. 2, B–D and Fig. 3).
Only H-2 Ld molecules loaded with 2C-reactive peptides,
peptides p2Ca, QL9, and SL9, expressed peptide/H-2Ld
epitopes that reacted with 2C TCR–Ig (Fig. 2, F–H and
Fig. 3). MCF increased z10–200-fold, from an MCF of 10
for either unloaded cells or cells loaded with an irrelevant
H-2 Ld–binding peptide, to as high as 2,200 for RMA-S Ld
cells loaded with peptide QL9 (Fig. 3). The pattern of reac-
tivity mimicked the known affinities of monovalent 2C TCR
Figure 1. Proposed structure and biochemical characterization of solu-
ble divalent TCR–Ig chimeras. A schematic of the chimeric protein
showing the TCR-a polypeptide (heavily shaded) linked to IgG1 heavy
chain and TCR-b polypeptide (lightly shaded) linked to Ig kappa light
chain is shown in A. The linkers between the chimeric chains consist of
glycine/serine spacers. Presumptive binding sites of mAb 1B2, an anticlo-
notypic 2C TCR-specific mAb, and anti–human Vb13.1-specific mAb
on the putative TCR–Ig structures are also noted. Detection of chimeras in
baculovirus supernatants (Fig. 1, B and C). Plates were coated with goat
anti–mouse Fc. For detection of TCR–Ig, the secondary antibody was bi-
otinylated and consisted of either the anti 2C mAb, 1B2 (B) or the anti–
human Vb13.1 TCR-specific mAb H131.21Y (C).
Figure 2. Soluble divalent 2C
TCR–Ig selectively reacts with
H-2 Ld molecules loaded with
peptides known to interact with
2C T cells. After overnight incu-
bation of RMA-S Ld cells at
278C, cells were cultured in the
presence or absence of various
H-2 Ld binding peptides: no
peptide cells maintained at 278C
(A and E), tum2 (B and F), p2Ca
(C and G), and QL9 (D and H)
were added to the cultures and
incubated as described in Materi-
als and Methods. Cells were then
harvested and processed for flow
cytometry analysis. Cells were
stained with either purified mAb
30.5.7 (A–D), or 2C TCR–Ig
culture supernatants (E–H) di-
luted to 20–40 mg/ml final con-
centration. In each panel, the
histogram of treated cells (solid
line) is contrasted with that of cells not treated with any peptide and cul-
tured for 1 h at 378C (broken line). Histograms shown are from one repre-
sentative experiment that has been repeated at least three times.
1Abbreviations used in this paper: LD, lethal dose; MCF, mean channel fluo-
rescence; MCMV, murine cytomegalovirus; pMCMV, H-2 Ld binding
peptide from pp89 of MCMV; pVSV, H-2 Kb binding peptide isolated
from VSV NP residues (52–59); sm, soluble monovalent; VSV, vesicular
stomatitis virus.1338 Analysis of Peptide–MHC Complexes by TCR–Ig
for peptide–H-2 Ld complexes (see Table 1 for affinities).
RMA-S Ld cells loaded with peptide QL9, p2Ca, or SL9
had MCF values of 2,200, 550, and 100, respectively,
when stained with 2C TCR–Ig. Thus, soluble divalent 2C
TCR–Ig chimeras reacted strongly with QL9–H-2 Ld
complexes, modestly with p2Ca–H-2 Ld complexes, and
weakly with SL9–H-2 Ld complexes. The fact that 2C
TCR–Ig bound to SL9-loaded H-2 Ld molecules indicates
that even in a direct flow cytometry assay, soluble divalent
2C TCR–Ig chimeras could be used to detect specific pep-
tide–MHC complexes that have affinities as weak as 71
mM for monovalent 2C TCR.
A6 TCR–Ig also demonstrated peptide specificity. This
was studied by peptide-loading T2 cells, a human HLA-A2
positive cell line that expresses empty MHC molecules and
can be readily loaded with specific peptides of interest (46,
47). When T2 cells were loaded with different peptides,
only cells loaded the A6-reactive peptide derived from tax
11–19, LLFGYPVYV, reacted with A6 TCR–Ig (Fig. 4, C
and D). MCF increased z20-fold, from an MCF of 21 for
either unloaded cells or cells loaded with an irrelevant
HLA-A2–binding peptide, M1, to 357 for T2 cells loaded
with the tax peptide. As expected, all HLA-A2–binding
peptides stabilized expression of the epitope recognized by
mAb BB7.2 (Fig. 4, A and B).
The peptide specificity of these two disparate TCR–Ig
chimeras indicates that the approach is a general one appli-
cable to multiple different TCRs. Soluble divalent TCR–
Ig chimeras have sufficiently high affinity to allow staining
of cognate peptide–MHC ligands in direct flow cytome-
try–based assays.
Affinity Measurements of Soluble Divalent TCR Interaction
with Peptide–MHC Complexes. To directly analyze the im-
pact of the divalent nature of TCR–Ig on affinity, a com-
petitive inhibition assay was developed to measure the af-
finity of soluble 2C TCR analogues for peptide–MHC
complexes. This assay, similar to one previously used to de-
termine the affinity of soluble monovalent 2C TCR for
peptide–MHC complexes (38), is based on mAb 30.5.7
binding to a region of the a2 helix of H-2 Ld that overlaps
with TCR receptor binding (44, 45). Hence, the affinity of
soluble TCR analogues can be measured in terms of their
inhibition of 30.5.7 binding.
To determine the affinity of the soluble 2C TCR ana-
logues, one has to first determine the Kd of 30.5.7 Fab frag-
ments for peptide-loaded H-2 Ld molecules. This measure-
ment was determined by direct saturation analysis of
30.5.7-FITC Fab binding to H-2 Ld molecules on the sur-
face of RMA-S Ld cells. RMA-S cells were chosen since
these cells express empty MHC molecules that can be
readily loaded with specific peptides of interest (36, 48).
The affinity of 30.5.7 for H-2 Ld molecules is dependent
on the peptide loaded into H-2 Ld (Table 2). The affinity
of the 30.5.7 for QL9-loaded H-2 Ld molecules is 12.2
nM, whereas the affinities for p2Ca, pMCMV (Table 2),
and SL9 (data not shown) loaded H-2 Ld molecules range
between 4.8–6.4 nM. These small, peptide-dependent, dif-
ferences in affinity are reproducible and variations in affin-
ity were accounted for in the competitive binding assays.
Figure 3. Soluble divalent 2C TCR–Ig retains the relative reactivity of
2C T cells towards specific peptide-stabilized H-2 Ld molecules. RMA-S
Ld cells were incubated under various conditions as described in Fig. 2.
Peptide stabilized H-2 Ld molecules were analyzed by flow cytometry as
described above. To facilitate comparison of peptide-stabilized H-2 Ld
molecules, data are presented as mean channel fluorescence.
Figure 4. Divalent A6 TCR–IgG selectively reacts with HLA-A2 mol-
ecules loaded with tax 11–19 peptides. T2 cells (106/ml) were incubated
overnight at 378C in the presence (thick lines) or absence (thin lines) of
peptides in a 96-well plate. Cells were then pelleted and coincubated on
ice with 20 ml of A6 TCR–Ig protein, with a final concentration of z10
mg/ml, for 1 h. The peptides used in this experiment were the HLA-A2–
binding peptides derived from HTLV-1 tax protein (11–19) LLF-
GYPVYV (B and D), and an HLA-A2–binding peptide derived from in-
fluenza M1, GILGFVFTL (A and C). Since peptides are resuspended in
50% DMSO, DMSO alone serves as a nonpeptide control. After the hour
incubation with A6 TCR–Ig, cells were then washed and incubated with
goat anti–mouse PE for an additional 1 h on ice, washed again, and resus-
pended in 250 ml of wash buffer. The experiments have been repeated at
least twice. Comparable data have been obtained using either culture su-
pernatants containing A6 TCR–Ig or purified A6 TCR–Ig. Representa-
tive histograms are shown.1339 O’Herrin et al.
These values are in good agreement with the previously
measured affinities of 125I–30.5.7 Fab for the same peptide–
H-2 Ld complexes (8.8–16 nM; reference 38).
2C TCR–Ig inhibited binding of 30.5.7 Fab to H-2 Ld
molecules loaded with either QL9 or p2Ca peptides, but
did not inhibit 30.5.7 Fab binding to pMCMV-loaded H-2
Ld molecules (Fig. 5). The affinity of soluble divalent 2C
TCR–Ig for QL9 loaded molecules is 13.3 nM (Fig. 5 and
Table 2). As expected, the affinity of 2C TCR–Ig for
p2Ca-loaded molecules, 90 nM, is lower than that for
QL9-loaded H-2 Ld. Although a small amount of competi-
tive inhibition was seen with SL9 loaded cells, the affinity
of the soluble divalent 2C TCR–Ig chimeras for SL9-
loaded molecules is too low to be accurately measured un-
der the conditions tested (data not shown).
In all cases analyzed, the affinity of the soluble divalent
2C TCR–Ig was significantly higher than the affinity of the
soluble monovalent 2C TCR for its cognate ligand (Fig. 5
and Table 2). The affinity of soluble divalent 2C TCR–Ig
was 50-fold higher for QL9-loaded H-2 Ld and at least 20-
fold higher for p2Ca-loaded H-2 Ld molecules than that of
soluble monovalent 2C TCR for the same peptide–MHC
complexes (Table 2). Thus, the divalent nature of soluble
2C TCR–Ig chimeras significantly increased the affinity of
the TCR analogue for its cognate ligands.
Binding of Soluble Divalent 2C TCR–Ig to Cognate Peptide–
MHC Ligands. As discussed above, in addition to recog-
nizing the alloreactive peptide–H-2 Ld ligands, additional
cognate ligands for 2C TCR have been defined. The 2C
TCR is also alloreactive on H-2 Kbm3. Both alloreactive
MHC molecules, H-2 Ld and H-2 Kbm3, mediate negative
selection of the 2C TCR in 2C transgenic mice. With re-
gard to the alloresponse on H-2 Kbm3, a single peptide–
MHC complex, dEV-8/H-2 Kbm3, has been defined (see
Table 1 for sequences) and is known to be a target for 2C
CTLs and the presumptive negatively selecting peptide–
MHC complex. In addition to alloreactive complexes for
2C CTL, an artificially derived peptide-dependent synge-
neic target has also been defined, SIY/H-2 Kb (see Table 1
for sequences). To analyze the ability of 2C TCR–Ig to
bind to these alternate 2C-reactive complexes, the binding
of 2C TCR–Ig to peptide-loaded transfected T2 cells was
studied. Since T2 cells are derived from a human cell line,
T2 cells do not naturally express H-2 Kb as do RMA-S
cells. Thus, to study the binding of 2C TCR–Ig to pep-
tide-loaded H-2 Kb or various H-2 Kbm mutant molecules,
the T2 system was chosen since it is not complicated by the
expression of MHC molecules from the parental cell line.
Similar to RMA-S Ld cells, T2 cells also express empty
MHC molecules that can be readily loaded with different
peptides. For these studies, T2 cells transfected with: H-2
Kb, T2 Kb; H-2 Kbm3, T2 Kbm3; and H-2 Kbm11, T2 Kbm11
(21, 22) were loaded with a variety of different MHC-
binding peptides.
Peptide SIY-loaded T2 Kb, T2 Kbm3, or T2 Kbm11 cells
all expressed epitopes recognized by 2C TCR–Ig (Fig. 6,
A–C). MCF of cells incubated with 2C TCR–Ig increased
z20-fold, from 14 for pVSV (H-2 Kb binding peptide iso-
lated from vesicular stomatitis virus NP residues) -loaded to
Table 2. Measured Affinities of TCR Analogues for
Peptide-loaded RMA-S Ld Cells
Peptide–MHC
complex
30.5.7 Fab 2C TCR–Ig 2C-sm TCR
Kd Kapp Kd Kapp Kd
nM nM nM nM nM
QL9 12.2 18.3 13.3 953.4 613.6
p2Ca 5.8 107.7 90.5 .2000* .2000*
pMCMV 4.8 ndc‡ ndc‡ ND§ ND§
*Competition was detected at the highest concentration of 2C-soluble
monovalent (sm)TCR used, but an accurate measure of the Kd could
not be determined.
‡ndc, no detectable competition with 30.5.7 Fab fragments.
§not determined.
Affinities of 30.5.7 Fab fragments for RMA-S Ld cells were determined
by direct saturation analysis of 30.5.7 Fab binding to cells analyzed by
flow cytometry. Cells were incubated with increasing amounts of FITC-
labeled 30.5.7 Fab, and Kd s were estimated from a plot of 1/MCF ver-
sus 1/[30.5.7 Fab]. Affinities of 2C TCR analogues were determined
by competition of the 2C TCR analogue with a constant amount of
FITC-labeled 30.5.7 Fab fragments for RMA-S Ld cells as described in
Materials and Methods. Kapp was calculated from a plot of 1/(percent
maximal 30.5.7 Fab binding) versus [2C TCR analogue]. The Kapp was
corrected for the affinity of 30.5.7 Fab for RMA-S Ld cells according to
the equation Kd,TCR 5 Kapp/(1 1 [30.5.7 Fab]/Kd,30.5.7) (38). The values
reported in the table are from one representative experiment that has
been repeated at least three times. Each data point used in determina-
tion of the Kd is the average of duplicate points.
Figure 5. The affinity of soluble divalent 2C TCR–Ig for peptide–H-2
Ld complexes is higher than that of soluble monovalent 2C TCR. RMA
S-Ld cells were loaded with peptides (QL9, h, and  ; p2Ca, e; or pM-
CMV, n) and subsequently incubated with a constant amount of FITC-
labeled 30.5.7 Fab and varying concentrations of either 2C TCR–Ig (solid
lines) or soluble monovalent 2C TCR (sm2C TCR; dashed line). Binding
of FITC–30.5.7 Fab was determined by flow cytometry. Plotted as the
percent maximal (no 2C TCR analogue) 30.5.7 binding versus the con-
centration of 2C TCR analogue. Apparent affinities were determined
from a replot of 1/(percent maximal 30.5.7 binding) versus [TCR ana-
logue] (see text and Table 2 for further discussion). Data shown are from
one representative experiment that has been repeated at least three times.
Each data point is the average of duplicates.1340 Analysis of Peptide–MHC Complexes by TCR–Ig
276 for SIY-loaded T2 Kb and from 16 for pVSV-loaded to
250 for SIY-loaded T2 Kbm11. SIY-loaded T2 Kbm3 cells
showed a much weaker but still significant interaction with
2C TCR–Ig (Fig. 6 B); compare SIY-loaded (solid lines;
MCF of 36) to pVSV-loaded (dotted lines; MCF of 12) T2
Kbm3 cells. The 2C TCR–Ig-binding data to SIY–MHC
complexes was consistent with 2C CTL-mediated lysis on
various SIY–MHC targets (Fig. 7). 2C CTL-mediated effi-
cient lysis of SIY-loaded T2 Kb and T2 Kbm11 cells (Fig. 7 B
and data not shown, 50% lethal dose (LD50) of z10 ng/ml
for SIY T2 Kb). 2C CTL-mediated lysis of SIY-loaded T2
Kbm3 cells was significantly less efficient (Fig. 7 C, LD50
z100 ng/ml).
The binding of 2C TCR–Ig to dEV-8–loaded cells re-
vealed a striking difference between the affinity of 2C
TCR–Ig for dEV-8–MHC complexes and the ability of
that same peptide–MHC complex to mediate lysis by 2C
CTLs. As expected, dEV-8–loaded T2 Kb cells were nei-
ther lysed by 2C CTL (Fig. 7 B), nor were they recognized
by 2C TCR–Ig in flow cytometry assays (Fig. 6 A). Unex-
pectedly, no significant binding of 2C TCR–Ig could be
found to dEV-8–loaded T2 Kbm3 cells (Fig. 6 B). MCF of
cells stained with 2C TCR–Ig was similar whether cells
were loaded with dEV-8 or control peptide pVSV (Fig. 6
B; compare dotted lines to dashed lines). This is most surpris-
ing in that, consistent with previous reports (22), dEV-8–
loaded T2 Kbm3 cells were efficiently lysed by 2C CTL
(Fig. 7 C). In fact, dEV-8–loaded T2 Kbm3 cells were much
better target cells (LD50 of z0.5–1.0 ng/ml) than SIY-
loaded T2 Kbm3 cells (LD50 of z100 ng/ml), where a sig-
nificant binding of 2C TCR–Ig was seen (Fig. 6 B). The
efficiency of lysis by 2C CTL of dEV-8–loaded T2 Kbm3
cells was on the same order of magnitude as that of p2Ca-
loaded T2 Ld cells (Fig. 7 A, LD50 of z0.5 ng/ml) which
was also efficiently recognized in the 2C TCR–Ig-binding
assay (Fig. 2 G). These findings were not due to poor bind-
ing of dEV-8 to H-2 Kbm3 molecules since peptide-loading
experiments showed that H-2 Kbm3 molecules were stabi-
lized equally well by both SIY and dEV-8 peptides (data
not shown). A similar, although less dramatic, lack of cor-
relation between cytolysis and 2C TCR–Ig binding was
seen for dEV-8–loaded T2 Kbm11 cells. dEV-8–loaded T2
Kbm11 cells are relatively poor targets for 2C CTL (refer-
ence 22 and data not shown), but were also not reactive
with 2C TCR–Ig in flow cytometry assays (Fig. 6 C).
Thus, a significant discrepancy exists between the affinity
of the 2C TCR for a naturally occurring alloreactive pep-
tide–MHC complex and the ability of that same complex
to mediate lysis of target cells exists.
Analysis of the Effects of g-IFN on Expression of Endogenous
2C-specific Peptide–MHC Complexes. The specificity and
affinity of 2C TCR–Ig for peptide–MHC complexes sug-
gested that one might be able to use this reagent to probe
the influence of lymphokines on endogenous, cell surface,
peptide–MHC complexes. To analyze this possibility and
follow the expression of endogenous 2C-reactive peptide–
H-2 Ld complexes within a heterogeneous peptide–MHC
environment, the influence of g-IFN on the H-2 Ld–express-
ing murine cell line RENCA was studied. RENCA cells
were cultured in the presence of variable amounts of g-IFN
to induce upregulation of naturally loaded peptide–MHC
complexes. 2C TCR–Ig binding to RENCA cells in-
creased as a function of g-IFN induction (Fig. 8, A–D, solid
lines). The effect of g-IFN was dose dependent with a
maximal two- to threefold increase seen on cells treated
Figure 6. Soluble divalent 2C
TCR–Ig detects SIY–MHC com-
plexes, but not dEV-8–MHC
complexes. T2 cells transfected
with either H-2 Kb, H-2 Kbm3,
or H-2 Kbm11 were incubated
overnight at 278C and loaded
with peptides dEV-8 (broken
line), SIY (solid line), or pVSV
(dotted line) as described in Mate-
rials and Methods. Cells were
stained with purified 2C TCR–
Ig (z50 mg/ml) and GAM-IgG-
RPE as described in Materials
and Methods, and analyzed by
FACSÒ. Resultant histograms are
shown; (A), T2-Kb cells, (B) T2-
Kbm3, (C), T2-Kbm11. In the his-
tograms presented 2C TCR–Ig
reactivity with either dEV-8 (bro-
ken line) or pVSV (dotted line) was
virtually identical leading to dif-
ficulty in discriminating between
these two histograms.
Figure 7. 2C CTL-mediated
lysis on various peptide–MHC
targets. T2 cells transfected with
either H-2 Ld (A), H-2 Kb (B),
or H-2 Kbm3 (C) were chromium
labeled as described and then
loaded with peptides by incubat-
ing at 258C for 1.5 h in the pres-
ence of variable amounts of pep-
tides: p2Ca (r) and pMCMV
(e) (A); and dEV-8 (n), SIY
(h), or pVSV (s) (B and C).
Peptide-loaded target cells were
then incubated at an effector to
target ratio of 10:1 and specific
lysis calculated as described in
Materials and Methods. Data
shown are representative of three
separate experiments.1341 O’Herrin et al.
with 10 U/ml of g-IFN. Since g-IFN is known to have a
direct effect on class I expression (Fig. 8, E–H and refer-
ence 23), it is necessary to normalize for any nonspecific
2C TCR–Ig binding secondary to increased expression of
H-2 Ld. This was accomplished by incubating RENCA
cells with a control irrelevant H-2 Ld–binding peptide from
pp89 of murine cytomegalovirus, pMCMV. Since p2Ca is
known to have a weak affinity for H-2 Ld (14, 15) ex-
change with a higher affinity H-2 Ld–binding peptide like
pMCMV (14) should be very efficient. Therefore, back-
ground reactivity of 2C TCR–Ig could be determined by
the efficient displacement of endogenous p2Ca or p2Ca-
like peptides by incubating the cells with saturating amounts
of the control pMCMV peptide. In all cases, 2C TCR–Ig
binding could be blocked by earlier incubation of cells with
the control H-2 Ld–binding pMCMV (Fig. 8, A–D, dotted
lines). Earlier incubation of RENCA cells with a 2C-spe-
cific peptide, QL9, induced a dramatic increase in 2C
TCR–Ig binding (data not shown). The results of these ex-
periments indicate that 2C TCR–Ig could be used to ana-
lyze the impact of cytokines on cell surface expression of
endogenous 2C-reactive peptide–MHC complexes.
The effect of g-IFN on 2C TCR–Ig reactivity was dis-
tinct from its effects on 30.5.7 reactivity. At all concentra-
tions analyzed, 5–50 U/ml, g-IFN induced a five to sixfold
increase in serologically reactive H-2 Ld, as recognized by
mAb 30.5.7 (Fig. 8, E–H). MCF of unstimulated RENCA
cells was 500, whereas the MCF of g-IFN–stimulated cells
was between 2,666 and 3,038. The maximal effect of g-IFN
was seen at the lowest dose used, in the experiment pre-
sented, 5 U/ml, and in other experiments was seen even at
dose of g-IFN as low as 1 U/ml (data not shown). Interest-
ingly, the dose response curve of g-IFN on 2C TCR–Ig
reactivity was shifted. g-IFN at 5 U/ml had a relatively
small, but significant effect on 2C TCR–Ig reactivity.
Maximal effects of g-IFN on 2C TCR–Ig reactivity re-
quired g-IFN treatment at 10 U/ml, z10-fold more than
needed for maximal effects of g-IFN on 30.5.7 reactivity.
These results indicate a differential effect of g-IFN on
MHC heavy chain expression than that of g-IFN on spe-
cific peptide antigen–MHC complex expression.
Discussion
Interest in understanding T cell–mediated immune re-
sponses led us to develop a general system for expression of
high affinity soluble analogues of TCR. This was accom-
plished using Ig as a molecular scaffold to generate soluble
divalent TCR analogues. The proof of the efficacy of this
approach was shown by the development of two different
TCR–Ig molecules, one derived from a TCR recognizing
a murine alloantigen, and the other from a TCR recogniz-
ing a viral peptide presented by human HLA-A2. The di-
valent nature of soluble TCR–Ig increased the affinity
z50-fold, as proven by measuring the values of both the
monovalent and divalent 2C TCR in a single system. The
divalent construct had an affinity for QL9-loaded H-2 Ld
molecules z50-fold higher than soluble monovalent 2C
TCR. Divalent 2C TCR–Ig also had an affinity for p2Ca-
loaded H-2 Ld molecules at least 20-fold higher than solu-
ble monovalent 2C TCRs. Although 2C TCR–Ig inter-
acted with SL9–H-2 Ld complexes, its affinity was too low
to accurately estimate under the conditions tested, yet it
was significantly higher than that of soluble monovalent 2C
TCR. Thus, for all ligands analyzed, significant increases in
affinity of the soluble divalent 2C TCR–Ig over soluble
monovalent versions of 2C TCR were found. This in-
crease in affinity enhanced our ability to use this reagent to
study peptide–MHC interactions.
Soluble divalent TCR–Ig used in flow cytometry assays
proved to be a sensitive way of analyzing TCR interaction
with peptide–MHC complexes. In our model system,
mean channel fluorescence of peptide-loaded RMA-S Ld
cells was concordant with the reported affinities of 2C
TCR for various peptide–MHC ligands. Using this rela-
tively simple assay we were able to detect interactions of
the 2C TCR with three different peptide–H-2 Ld com-
plexes. These peptide–MHC complexes reflect an affinity
range of over three orders of magnitude, from 0.066 to 71
mM for monovalent 2C TCR (14). This range of affinities
is thought to reflect most of the range of known class I-spe-
cific TCR interactions with either peptide agonists–MHC
or peptide antagonist–MHC complexes (49–52). Although
soluble monovalent 2C TCR was useful in the direct flow
Figure 8. Modulation of endogenous 2C-specific peptide–H-2 Ld
complexes on the surface of RENCA cells by g-IFN. RENCA cells were
cultured for 48 h with 0 (A and E), 5 (B and F), 10 (C and G), or 50 (D
and H), U/ml g-IFN. As described in Results, g-IFN is known to have a
direct effect on class I expression, making it necessary to establish back-
ground binding of 2C TCR–Ig to g-IFN–treated cells. This was accom-
plished by incubating RENCA cells with saturating amounts of the H-2
Ld–binding peptide, MCMV, which efficiently displaced the endogenous
H-2 Ld–bound peptides, including any 2C-reactive peptides. Cells were
harvested, stained with 2C TCR–Ig (75 mg/ml; A–D) or the mAb 30.5.7
(45 mg/ml; E–H) as described in Materials and Methods. Cells were sub-
sequently stained with GAM-IgG-RPE and analyzed by FACSÒ. Result-
ant histograms are shown. Solid lines represent histograms of cultures
with no added peptide, whereas dotted lines represent histograms from
cultures incubated with pMCMV. All experiments were done in dupli-
cate and repeated at least three times. Note the differences in the extents
of fluorescence (see the scales on the histograms) upon staining with 2C-
TCR–Ig versus staining with 30.5.7.1342 Analysis of Peptide–MHC Complexes by TCR–Ig
cytometry assay only with the highest affinity QL9/H-2 Ld
MHC complexes (data not shown), no reactivity could be
seen between the soluble monovalent 2C TCR and one of
the natural ligands, p2Ca, or the low affinity peptide, SL9
(data not shown). We were unable to detect the very weak
interactions occurring between 2C TCR and p2Ca/H-2
Kb molecules (data not shown and reference 14). The affin-
ity of this interaction has been measured as 333 mM (14)
suggesting a lower limit of detection of peptide–MHC
complexes using soluble 2C TCR–Ig in a flow cytometry
based assay.
The affinities measured for soluble monovalent 2C TCR
in our system are about an order of magnitude different
than previously measured affinities for soluble monovalent
2C TCR (12, 14, 15). Using a competitive 1B2 binding as-
say, investigators estimated an affinity of 66 nM for the in-
teraction of 2C TCR with QL9-loaded H-2 Ld molecules
and 500 nM for its interaction with p2Ca-loaded H-2 Ld
molecules (14). Differences in assay systems, including in-
volvement of the CD8 coreceptor probably account for the
order of magnitude weaker affinity we measured for solu-
ble monovalent 2C TCR. Recent work supporting this
view has shown that CD8 enhances the affinity of TCR for
certain peptide–MHC complexes z10-fold (53, 54).
Using 2C TCR–Ig, an unexpected finding was revealed
in analysis of the affinity of 2C TCR binding for cognate
peptide–MHC complexes. Binding of 2C TCR–Ig to pep-
tide-loaded syngeneic MHC complexes displayed a strict
correlation with the CTL data. 2C TCR–Ig binding to
dEV-8–H-2 Kb was undetectable, whereas binding to SIY–
H-2 Kb was quite strong. Surprisingly, binding of 2C
TCR–Ig did not correlate with efficacy of lysis for the allo-
geneic MHC, H-2 Kbm3. No binding of 2C TCR–Ig could
be detected to the naturally occurring allogeneic peptide
dEV-8–H-2 Kbm3 complex. The lack of 2C TCR–Ig bind-
ing occurred despite the fact that dEV-8–H-2 Kbm3 is more
efficient in mediating lysis by 2C CTL than SIY–H-2 Kb
and that 2C TCR–Ig binding to SIY–H-2 Kbm3 could eas-
ily be detected. Our experiments using 2C TCR–Ig dem-
onstrate that the affinity of the 2C TCR for the dEV-8–H-2
Kbm3 complex is weaker than 71 mM. This is based on the
fact that although 2C TCR–Ig recognized SL9–H-2 Ld com-
plexes (Fig. 3), an interaction known to have an affinity of
71 mM (14), 2C TCR–Ig did not recognize dEV-8–H-2
Kbm3. Therefore, the affinity of 2C TCR for dEV-8–H-2
Kbm3 must be weaker than 71 mM. This is particularly im-
portant in view of the fact that allogeneic MHC targets are
thought to be relatively high affinity ligands, affinities of
1–0.1 mM for cognate TCR interactions (14, 15). Since in
normal allogeneic responses, the T cell repertoire has not
been negatively selected, some investigators have proposed
that the TCR interaction with allogeneic MHC will rou-
tinely be of higher affinity than TCR interactions with
peptide–MHC complexes that have passed through nega-
tive selection (15). Based on the previously estimated affin-
ities of negatively selecting peptide–MHC complexes, one
would have expected that the 2C TCR would not be neg-
atively selected on H-2 Kbm3. However, in transgenic 2C
TCR animals, the allogeneic H-2 Kbm3 MHC molecule
serves as a mediator of negative selection in the thymus (20).
Thus, assuming dEV8–H-2 Kbm3 is a negatively selecting
complex, the intrinsic affinity of peptide–MHC complexes
required to mediate negative selection is significantly lower
than previously predicted.
Previously, a lack of a correlation between TCR affinity
and efficiency of lysis by CTLs was noted with certain vari-
ant p2Ca peptides, not naturally occurring endogenous
peptides, on H-2 Ld (16). From that work, investigators
concluded that other factors such as CD8, which are not
part of soluble TCR analogues, could be influencing the af-
finity of the TCR for its peptide–MHC ligand, thereby,
impacting on the lysis of targets pulsed with these peptides.
As mentioned above, this hypothesis is supported by recent
work showing the enhancement of the interaction between
TCR and peptide–MHC complexes by CD8 (54). Our
analysis of the 2C TCR–Ig reactivity, which was unable to
detect certain 2C-reactive complexes, dEV-8–H-2 Kbm3
complexes, may also reflect a differential importance of
CD8 engagement in facilitating lysis of certain peptide–
MHC targets over others.
By analyzing the expression of endogenous cell surface
peptide–MHC complexes, we found that the effect of g-IFN
on regulation of class I heavy chain is distinct from its effect
on regulation of the peptide–MHC complexes. This could
reflect different target genes for the two activities of g-IFN.
Presumably the effects of g-IFN on class I heavy chain ex-
pression is due the g-IFN–responsive element in the class I
MHC promoter. The effects on expression of the epitope
recognized by 2C TCR–Ig could be due to the effects of
g-IFN on peptide processing, as recently found to relate to
induction of the proteosome component PA28 (24, 25,
28), or at other potentially more complex g-IFN–con-
trolled pathways involved in regulation of antigenic peptide
delivery. Of interest when the effect of the proteasome
regulator PA28a on antigen presentation was studied using
cells transfected with PA28a, investigators saw an approxi-
mate threefold increase in alloreactive C57BL/6 anti-
BALB/c responses. This effect is similar in magnitude to
the effect of g-IFN on 2C TCR–Ig binding.
In addition to using soluble divalent high affinity TCR
as a general approach to study expression of peptide–MHC
complexes, mAbs that differentiate between MHC mole-
cules on the basis of peptides resident in the groove are also
useful in studying expression of specific peptide–MHC
complexes. As previously discussed, using both conven-
tional approaches and a recombinant antibody phage dis-
play library, a few such antibodies have been produced (3–
8). The mAb made using a recombinant antibody phage
display library (8) has affinities generally comparable to the
affinity of the soluble 2C TCR–Ig for high affinity pep-
tide–MHC ligands. A distinct advantage of soluble high af-
finity TCR–Ig chimeras is that even in the absence of any a
priori knowledge about their ligands, they may be useful in
defining the specific ligands recognized by poorly defined
TCR such as g/d TCR, undefined tumor-specific T cells,
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ation of mAbs specific for a particular peptide–MHC com-
plex requires the prior identification of the peptide ligand
for development and obviously cannot be used to help de-
fine the TCR ligands or the peptide–MHC complex. Fur-
thermore, T cell activation requires cross-linking of multi-
ple TCRs. Since the mode of interaction of TCR–Ig
chimeras with peptide–MHC complexes is similar to that
of the natural TCR, TCR–Ig will mimic the interaction of
a T cell with APCs and may help facilitate elucidation of bio-
chemical interactions involved in TCR recognition of pep-
tide–MHC complexes. Although mAbs with high affinity
for specific peptide–MHC complexes will cross-link TCR,
there is no guarantee that they will mimic the interaction
of TCR with peptide–MHC ligands. Thus, one can expect
that use of high affinity biologically relevant cognates such
as TCR–Ig molecules is likely to reveal details of TCR in-
teractions with peptide–MHC molecules that peptide-spe-
cific mAbs may miss. Advantages offered by both systems
will facilitate the analysis of expression of specific peptide–
MHC complexes in both normal and aberrant immune re-
sponses.
Here we presented a general approach for producing sol-
uble divalent versions of heterodimeric proteins such as T
cell receptors. This is the first time that soluble high affinity
and specificity analogues of TCR proteins have been made.
This approach is not only of relevance for TCR, but also
for other immunoregulatory proteins such as class II MHC
molecules (O’Herrin, S.M., M.S. Lebowitz, and J.P.
Schneck, manuscript in preparation), and potentially useful
in other cell biological systems involving heterodimeric in-
tegral membrane proteins. The experimental system de-
scribed here outlines a general approach of using divalent
high affinity ligands to study cell–cell interactions, driven
by multivalent ligand–receptor interactions.
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